Thermo Fisher Scientific Inc.
TMOLast close · Oct 16, 2026690.00−6.49 (−0.93%)
Market cap$255.1B
10 firms' latest targets, last 90 days: median $730.00 ($600.00–$750.00), 6% above the last close.
Price and published targets
Each firm's latest target
| Date | Firm | Target | Change | Vs price now |
|---|---|---|---|---|
| 2026-10-15 | RBC Capital | $740.00 | ▲ 28% | +7% |
| 2026-10-15 | Guggenheim | $740.00 | — | +7% |
| 2026-10-12 | Morgan Stanley | $730.00 | ▲ 12% | +6% |
| 2026-10-07 | Barclays | $750.00 | ▲ 15% | +9% |
| 2026-09-25 | Deutsche Bank | $720.00 | — | +4% |
| 2026-09-08 | UBS | $730.00 | ▲ 19% | +6% |
| 2026-09-03 | CLSA | $748.00 | — | +8% |
| 2026-08-05 | Stifel | $650.00 | ▲ 8% | -6% |
| 2026-07-27 | Piper Sandler | $600.00 | ▲ 18% | -13% |
| 2026-07-23 | Jefferies | $630.00 | — | -9% |
Consensus estimates
| FY | Revenue | YoY | EPS | YoY | Revenue range | EPS range | Analysts |
|---|---|---|---|---|---|---|---|
| 2023reported | $42.9B | -5% | $15.45 | -12% | est. $42.7B+0% | est. $21.52 | 17 |
| 2024reported | $42.9B | +0% | $16.53 | +7% | est. $42.8B+0% | est. $21.70 | 17 |
| 2025reported | $44.6B | +4% | $17.74 | +7% | est. $44.3B+1% | est. $22.75 | 18 |
| 2026 | $47.9B | +7% | $25.14 | +11% | $47.6B–$48.1B | $25.02–$25.22 | 20 |
| 2027 | $50.4B | +5% | $27.49 | +9% | $50.0B–$51.0B | $26.45–$29.03 | 20 |
| 2028 | $53.5B | +6% | $30.34 | +10% | $52.7B–$55.3B | $26.98–$32.70 | 17 |
| 2029 | $57.0B | +7% | $34.01 | +12% | $56.6B–$58.0B | $33.66–$34.73 | 13 |
| 2030 | $59.2B | +4% | $37.35 | +10% | $58.7B–$60.2B | $36.97–$38.14 | 8 |
Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.